Lonimecgene renparvovec efficacy and safety
6 evidence topics · 16 sources
Summary: REVEAL Part A pooled phase 1/2 efficacy at the May 2026 data cutoff
- Population and follow-up: REVEAL Part A pools two first-in-human, open-label phase 1/2 dose-escalation trials of a single lumbar intrathecal administration, one in females aged 12 years and older (NCT05606614 Part A, registered for ages 12 to under 22 years) and one in females aged 5 to 8 years (NCT06152237), each with 6 participants enrolled. As of the May 2026 data cutoff, 12 participants aged 6 to 21 years at dosing had received TSHA-102 (low dose of 5.7x10^14 total vector genomes, 4 participants; high dose of 1x10^15 total vector genomes, 8 participants), with baseline CGI-S scores of 4 to 6 and post-treatment follow-up of 12 to 30 months. Results at 6 and 12 months include all 12 participants, and results at 18 months or more include 7.
- Developmental milestones: the response rate, defined as the percentage of participants who gain or regain at least 1 of 28 developmental milestones assessed by multiple independent central raters through video evidence, was 83% (10 of 12) at 6 months, 100% (12 of 12) at 12 months, and 100% of 7 participants at 18 months or more. At 12 months or more, the poster reports 310 functional gains and improvements (about 26 per participant), comprising 31 developmental milestones and 279 additional skill gains or improvements, with 16 milestones in 6 pediatric participants and 15 in 6 adolescent or adult participants; milestone gains increased by 69% from 6 to 12 months. The additional skills comprised 53 MSEL-A skill gains, 128 ORCA skill gains, and 98 R-MBA improvements, with ORCA data for 8, MSEL-A data for 7, and R-MBA data for 12 participants.
- Clinician-rated scales: the mean R-MBA change from baseline was -11.0 at 6 months against -0.81 in the natural history comparison (P = 0.0011) and -10.3 at 12 months against -0.62 (P = 0.0002), and -11.0 at 18 months or more (P = 0.0046). All participants (100%) had a CGI-I score of 3 or less at multiple post-treatment assessments at each time point, and the proportion with CGI-S improvement was 25% at 6 months, 25% at 12 months, and 57% at 18 months or more.
Summary: dose comparison in REVEAL Part A
- The 2026 poster (May 2026 data cutoff) and the company's June 2026 program update presentation report an average score of -15.7 in the high-dose cohort and -7.8 in the low-dose cohort, which the presentation gives for 18 months or more after dosing. At the May 2026 data cutoff, treatment-related adverse events occurred in 5 high-dose participants (20 events) and 4 low-dose participants (17 events).
- The earlier 2025 poster reported, for the low-dose and high-dose cohorts respectively, a developmental milestone responder rate at 6 months of 75% and 83%, a mean R-MBA improvement of -9.8 and -12.2 at 6 months and -11.5 and -18.0 at 9 months or more, a mean CGI-I score of 2.3 and 2.0 at 6 months and 2.8 and 1.0 at 9 months or more, and CGI-S improvement at the latest visit in 25% and 33% of participants. The company Form 10-K gives the high-dose 6-month response as 83% (5 of 6 participants; May 2025 data cutoff).
- The high dose of 1x10^15 total vector genomes was carried into the pivotal trial and, scaled for brain volume, into ASPIRE.
Summary: REVEAL Pivotal design and status
- Design: the REVEAL pivotal trial (Part B of NCT05606614) is a single-arm, open-label study of a single lumbar intrathecal administration of the high dose (1x10^15 total vector genomes) in females aged 6 to under 22 years with Rett syndrome due to an MECP2 loss-of-function mutation who are in the developmental plateau population, with each participant serving as their own control. Central raters assessing milestone gain or regain from videos are blinded to the timing of each video.
- Endpoints and analysis: the primary endpoint is the response rate, the percentage of participants who gain or regain at least 1 of 28 natural history defined developmental milestones across communication, fine motor, and gross motor domains. Key secondary endpoints are the average number of milestones gained or regained per participant, the R-MBA, and the CGI-I. The null hypothesis, derived from natural history data, is a response rate of 6.7% (1 of 15 participants aged 6 years or older), and a response rate of 33% (5 of 15) is the minimum threshold for success. The statistical analysis plan names a 12-month primary analysis, and the company reports FDA alignment on a potential BLA submission based on a 6-month interim analysis.
- Status: the first participant was dosed in December 2025, and dosing was completed in 17 participants against a planned 15. The interim analysis is expected after all 17 participants complete 6 months of follow-up, with topline data and FDA feedback on the BLA submission pathway expected in the first half of 2027. No efficacy results have been reported.
Summary: ASPIRE design and status
- ASPIRE (NCT07480564) is an open-label study of the safety, tolerability, and preliminary efficacy of a single intrathecal administration of TSHA-102 at 1x10^15 total vector genomes adjusted for brain volume, given by lumbar puncture, in females aged 2 to less than 4 years with typical Rett syndrome. The primary endpoint is the proportion of participants with any treatment-emergent adverse event and serious adverse event from baseline through week 25, followed by an extended observation period through 5 years.
- The study started on 2026-05-08, with estimated primary completion in 2031-06, and is registered as active, not recruiting. Enrollment was planned at 3 participants, and the company completed dosing in 4.
- The company reports written FDA alignment that the planned BLA will include at least 3 months of safety data from 3 participants aged 2 to under 4 years in ASPIRE, while efficacy data from REVEAL pivotal participants aged 6 to under 22 years are to represent children aged 2 to under 6 years. No ASPIRE-specific efficacy or safety results have been reported.
Summary: safety
- REVEAL Part A (May 2026 data cutoff, 12 participants): treatment-related treatment-emergent adverse events occurred in 9 participants (37 events), serious treatment-emergent adverse events unrelated to TSHA-102 in 7 participants (17 events), and no participant had a treatment-related serious adverse event or a dose-limiting toxicity. All treatment-related events were mild to moderate; the most common were elevated liver enzymes (4 participants, 33%), increased cerebrospinal fluid protein (3, 25%), and pyrexia (3, 25%). The 2025 poster reported that most liver enzyme elevations were below 2 times the upper limit of normal and that acute excursions above 5 times the upper limit of normal were less common, asymptomatic, and responsive to steroid treatment.
- Immunosuppression: immunoprophylaxis with oral prednisolone and sirolimus begins 7 days before dosing, with the prednisolone taper planned from week 17 to week 25 and the sirolimus taper from week 38 in the pediatric protocol design. In the company's 2024 first-cohort data presentation, 34 treatment-emergent adverse events had occurred as of 05/10/2024, 33 of them mild or moderate; the most common was vomiting (5 events), a known risk of sirolimus, and 8 nonserious events were related to immunosuppression (2 vomiting events, dermatitis acneiform, cystatin C increase, blisters, myopathy, chronic renal disease, and a second myopathy). One severe, grade 3 serious adverse event, a change in seizure presentation, was judged unrelated to TSHA-102.
- REVEAL Pivotal: the company reported no treatment-related serious adverse events or dose-limiting toxicities in the REVEAL pivotal trial as of the March 2026 data cutoff, and its announcement of completed pivotal dosing reported none as of the June 2026 data cutoff without naming the trials that statement covers. In July 2026, about 6 weeks after dosing, one participant had a treatment-related, moderate Grade 2 event of peripheral sensory neuropathy, which the company describes as an expected risk of AAV therapy; the event was classified as a serious adverse event because the participant was admitted overnight under the treating institution's protocol. The company reports that the participant was discharged the following day and had nearly returned to baseline over the following three months.
- Pooled across REVEAL Phase 1/2 (12), REVEAL pivotal (17), and ASPIRE (4), the company reports no severe treatment-related serious adverse events or dose-limiting toxicities in 33 participants as of the November 2026 data cutoff, with all participants past the acute post-dosing safety monitoring period.
Summary: limitations of the evidence
- Sample size: efficacy data come from 12 participants in REVEAL Part A, 4 at the low dose and 8 at the high dose, with 7 contributing results at 18 months or more. The pivotal trial dosed 17 participants and ASPIRE dosed 4, and neither has reported efficacy results.
- Design: all three trials are open label. The pivotal trial is single arm with each participant serving as their own control, and the 2026 poster describes REVEAL as using each participant as their own control. The pediatric Part A trial is registered with no masking, and in NCT05606614 only the central raters of milestone videos are masked, to the timing of each video. The R-MBA and CGI-I are clinician-assessed measures and ORCA is a caregiver report. The registered primary outcome of the Part A trials is the incidence of treatment-emergent adverse events and serious adverse events.
- External comparator: Part A R-MBA results are compared with natural history samples of 75 participants at 6 months and 196 at 12 months, with MBA scores converted to R-MBA. The pivotal null response rate of 6.7% is derived from natural history data, in which first-time milestone gain after 6 years of age was below 3% across milestones and spontaneous first-time gain of a single milestone before 6 years of age was as high as 97%. The FDA draft guidance on small-population trials states that objectively measured endpoints that are not effort-dependent are critical for interpreting self-controlled or other non-blinded trials. A poster on the natural history analysis cites ethical and methodological concerns with sham controls and functional unblinding from required immunosuppression as obstacles to a controlled design.
- Source of data: the results come from company press releases, SEC filings, investor presentations, and congress posters. The 2025 poster states that its data reflected the electronic data capture system and were subject to change. Pivotal-trial safety is reported mostly as pooled statements across 33 participants, and efficacy in children aged 2 to under 6 years is to be extrapolated from older participants.